73 completed, 8 terminated, 5 unknown, 4 recruiting. 45 Phase 2, 28 Phase 1, 12 Not applicable, 5 Phase 3.
Follow Hodgkin's Disease: new trials by email Literature Review of Hodgkin's Disease trials Research Report on Hodgkin's Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant, Nivolumab, Brentuximab vedotin - Hodgkin's Disease | Phase 3 | Terminated | Bristol-Myers Squibb | 23 | 2017-06-26 | 2024-01-10 |
| Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices Hodgkin's Disease | Completed | Bristol-Myers Squibb | 290 | 2016-10-07 | 2021-12-15 | |
| Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies BL-8040, Leukapheresis, Hematopoietic cell transplant - Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Completed | Washington University School of Medicine | 50 | 2016-03-31 | 2023-11-07 |
| Pilot Study Exploring the Use of Hyperbaric Oxygen in Autologous Peripheral Blood Stem Cell Transplantation Administration of hyperbaric oxygen - Multiple Myeloma, Hodgkin's Disease | Not applicable | Unknown | University of Kansas Medical Center | 20 | 2014-03-01 | 2017-02-14 |
| Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination allogeneic donor derived B-lymphocytes - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Unknown | University of Erlangen-Nürnberg Medical School | 15 | 2013-11-01 | 2014-03-26 |
| P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies Infusion of one MPC expanded cord unit and one unexpanded cord unit, Infusion of two unexpanded cord blood units. - Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia | Phase 3 | Completed | Mesoblast, Ltd. | 49 | 2013-08-01 | 2020-06-26 |
| Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell Transplant Hodgkin's Disease, Non Hodgkin's Lymphoma | Completed | Duke University | 48 | 2013-08-01 | 2016-05-05 | |
| A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor Plerixafor - Related Donors Donating Peripheral Blood Stem Cells (PBSC) to a Family Member, Acute Myelogenous Leukemia | Phase 2 | Completed | Center for International Blood and Marrow Transplant Research | 127 | 2013-05-01 | 2023-09-14 |
| Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE EBV-specific T cells: A, EBV-specific T cells: B - Hodgkin's Disease, Non-Hodgkin's Lymphoma | Phase 1 | Recruiting | Baylor College of Medicine | 136 | 2013-01-14 | 2026-03-02 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease TG-0054 - Multiple Myeloma, Non-hodgkin's Lymphoma | Phase 2 | Completed | GPCR Therapeutics, Inc. | 12 | 2012-10-01 | 2021-04-19 |
| Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma Everolimus, Rituximab - CD20+, B-cell Lymphomas, Mantle Cell Lymphoma | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 56 | 2012-09-01 | 2021-10-26 |
| Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit Single FT1050 treated UCB unit - Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease | Phase 1 | Completed | Fate Therapeutics | 10 | 2012-01-01 | 2016-09-12 |
| Study Comparing R-mabHD and a Combination of ABVD in Hodgkin's Disease R-mabHD, ABVD - Hodgkin's Disease | Phase 2 | Unknown | American Scitech International | 120 | 2011-07-01 | 2011-07-20 |
| Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic Diseases Peripheral Blood Stem Cell Transplant - Chronic Leukemia, Acute Leukemia | Phase 2 | Completed | Northside Hospital, Inc. | 30 | 2011-04-01 | 2016-01-14 |
| Cyclophosphamide as Sole Graft-Versus-Host-Prophylaxis After Allogeneic Stem Cell Transplantation Cyclophosphamide - Multiple Myeloma, Non-Hodgkin-Lymphoma | Phase 2 | Completed | University of Cologne | 11 | 2011-03-01 | 2014-06-10 |
| A Study Of Panobinostat In Children With Refractory Hematologic Malignancies Panobinostat, Cytarabine - Lymphoblastic Leukemia, Acute, Childhood, Myelogenous Leukemia, Acute, Childhood | Phase 1 | Completed | Therapeutic Advances in Childhood Leukemia Consortium | 30 | 2011-03-01 | 2015-11-24 |
| Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies NiCord® - Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML) | Phase 1 / Phase 2 | Completed | Gamida Cell ltd | 12 | 2010-11-01 | 2021-08-03 |
| Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies Methotrexate, Pentostatin - Acute Lymphoblastic Leukemia, Acute Myelocytic Leukemia | Phase 3 | Completed | St. Jude Children's Research Hospital | 6 | 2010-09-01 | 2013-03-21 |
| MSC and HSC Coinfusion in Mismatched Minitransplants Mesenchymal stem cells, Isotonic solution - Leukemia, Myeloid, Acute, Leukemia, Lymphoblastic, Acute | Phase 2 | Terminated | University of Liege | 39 | 2010-07-01 | 2021-09-08 |
| Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor Total Body Irradiation (TBI), Donor Lymphocyte Infusion (DLI), Cyclophosphamide - Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 28 | 2010-07-01 | 2025-05-16 |
Showing 20 of 94. Sign in to see all of them.
Hodgkin Disease (94) · Lymphoma, Non-Hodgkin (52) · Multiple Myeloma (28) · Lymphoma (27) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (25) · Leukemia, Myeloid, Acute (21) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (20) · Myelodysplastic Syndromes (18) · Leukemia, Lymphocytic, Chronic, B-Cell (17) · Leukemia (14) · Hematologic Neoplasms (9) · Recurrence (8) · Graft vs Host Disease (7) · Neoplasms, Plasma Cell (7) · Anemia, Aplastic (6)
Hemic and Lymphatic Diseases (94) · Immune System Diseases (94) · Immunoproliferative Disorders (94) · Lymphatic Diseases (94) · Neoplasms by Histologic Type (94) · Lymphoproliferative Disorders (92) · Neoplasms (92) · Lymphoma (67) · Hematologic Diseases (50) · Hemorrhagic Disorders (29) · Blood Protein Disorders (28) · Cardiovascular Diseases (28) · Disease Attributes (28) · Hemostatic Disorders (28) · Paraproteinemias (28)
Cyclophosphamide (8) · fludarabine (7) · Melphalan (6) · Granulocyte Colony-Stimulating Factor (5) · Tacrolimus (5) · Antilymphocyte Serum (4) · Doxorubicin (4) · Etoposide (4) · Filgrastim (4) · Gemcitabine (4) · Rituximab (4) · Vinblastine (4) · plerixafor (4) · Alemtuzumab (3) · Bleomycin (3)
Dana-Farber Cancer Institute (9) · Memorial Sloan Kettering Cancer Center (9) · M.D. Anderson Cancer Center (5) · National Cancer Institute (NCI) (4) · Baylor College of Medicine (3) · Bristol-Myers Squibb (3) · Genzyme, a Sanofi Company (3) · Indiana University (3) · University Health Network, Toronto (3) · Bayside Health (2) · Duke University (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (2) · St. Jude Children's Research Hospital (2) · Stanford University (2)
United States (76) · Germany (4) · Canada (3) · Australia (2) · France (2) · Israel (2) · Belgium (1) · Hungary (1) · Italy (1) · Japan (1) · Netherlands (1) · Puerto Rico (1) · Russia (1) · Singapore (1) · Spain (1)
Andrea K. Ng, MD (3) · Andrew Spencer, Assoc. Prof (2) · Corey Cutler, MD, MPH (2) · David Porter, MD (2) · David Rizzieri, MD (2) · David Straus, MD (2) · Helen E Heslop, MD (2) · Mitchell Horwitz, MD (2) · Neal Flomenberg, MD (2) · Paolo Anderlini, MD (2) · Patrick Stiff, MD (2) · Robert Nelson, MD (2) · Tanya Trippett, MD (2)
PMID 20107229, PMID 20661232, PMID 21163927, PMID 21917759, PMID 22009536, PMID 22198152, PMID 23248254, PMID 23610104, PMID 23891588, PMID 23913470, PMID 24269380, PMID 24911148, PMID 25665464, PMID 26858124, PMID 29234922, PMID 29315015, PMID 29477778, PMID 30125215, PMID 30890544, PMID 32338562, PMID 38467031, PMID 38640255, PMID 39908567, PMID 40156952, PMID 40802906
2017 (1), P50CA126752 (1), R21CA106177 (1)